Kornimate/medical-research-clean huggingface dataset:
post-treatment surveillance in lung cancer

Conditions: Lung Cancer

Summary: there are 13.7 million americans currently living with a history of cancer. with continued improvements in cancer treatment and increasing life expectancy, this number is expected to reach nearly 18 million within the next decade. the care of these cancer patients, including surveillance during the post-treatment survivorship phase, is an increasingly important major health care concern and expenditure. as the fourth leading diagnosis among cancer survivors, lung cancer is emerging as a chronic problem that currently affects over 450,000 americans and is expected to grow by nearly 20% by 2022. lung cancer is the second most common cancer in the united states. of the estimated 182,550 patients newly diagnosed with non-small cell lung cancer (nsclc) this year, approximately 35% will present with localized disease and be eligible for curative resection. for patients with limited nsclc, surgical resection is the most effective method of controlling the primary tumor and provides the best opportunity for cure. a recent analysis by this group demonstrated that the number of lung cancer resections has increased over the past decade, with over 45,000 lung cancer resections performed annually in the us. this research will address a critical gap in knowledge because the optimal approach to post-treatment surveillance following lung cancer resection is unknown. the intensity of recommended surveillance visits ranges from every 3 months during the first two years to an annual visit. imaging modalities range from ct scans to chest radiographs to no routine imaging for asymptomatic patients. the reason for these significant differences is a lack of quality data on lung cancer surveillance and clinical guidelines based largely on small retrospective analyses and expert opinion. the national cancer data base (ncdb) provides real world national lung cancer resection and surveillance data on over 70% of newly diagnosed lung cancers from more than 1,500 institutions. this study will compare the effectiveness of the three most common surveillance intensities (ct scans every 3 months vs. 6 months vs. annually) on the stakeholder selected outcome of survival. all analyses will be risk adjusted for differences in patient characteristics at baseline, including tumor characteristics, patient age, comorbid disease, and other potential confounders. analyses will also be adjusted for the competing risk of death.

this study will use a special study of the national cancer database to develop a cohort of nsclc survivors undergoing surveillance. cox proportional hazards regression and competing risk analyses will compare the effectiveness of the three most common surveillance intensities (3 months vs. 6 months vs. annually) on survival. there is also a plan to engage cancer survivors to guide the development of our study comparators, outcomes and demonstration of results.

Eligibility criteria:
inclusion criteria: * men or women * diagnosis of surgically resected lung cancer * american joint committee on cancer (ajcc) stages i-iii exclusion criteria: -
the efficacy of honey on improving the post surgical course after tonsillectomy in children-prospective study

Conditions: Postoperative Pain

Summary: the aim of this study is to investigate the effect of honey administration on pain following pediatric tonsillectomy or adenotonsilectomy. the patients( children 2-18 years old) will divide into two groups by simple randomization method( the control group and the case group). after surgery the case group: would instructed to use honey twice a day( 5 ml- one tea spoon each time)+acetaminophen syrup+ syrup oxycode( as necessary). the control group would get as is customary in our ent department :acetaminophen syrup+ syrup oxycode( as necessary). the families would ask to follow treatment protocols for 7 days. from the first to the 7th day after the operation , the parents would ask to fill a questionnaire every day for assessment of pain intensity by visual analouge scale(vas) , the numbers of painkillers taken daily, the number of times the child awaking at night due to pain, the amount of fluids intake daily, the time of commencement of regular oral intake. patient would follow up 7-14 days after surgery.

this study was approved by the regional ethics committe of the hospital. the participants would be: children (2-18 years old, male and female), who will have the indication of tonsillectomy and will undergo classic tonsillectomy with or without adenoidectom in otolaryngology departement in haemek hospital and they ate already honey in their lives. exclusion criteria: * allergy to honey * allergy to acetaminophen * patients with diabeties mellitus * pregnent/breast feeding patients * patients with coagulation disorders * patients who undrego another operation in addition to tonsillectomy with or without adenoidectomy ( except insertion of ventilation tubes surgery).

Eligibility criteria:
inclusion criteria: * children ages 2-18 years old that candidates for tonsillectomy with or without adenoidectomy surgery, in otolaryngolgy department , haemek hospital, afula. * parents' signature on informed consent form. exclusion criteria: * allergy to honey * allergy to acetaminophen * patients with diabeties mellitus * pregnent/breast feeding patients * patients with coagulation disorders * patients who undrego another operation in addition to tonsillectomy with or without adenoidectomy ( except insertion of ventilation tubes surgery).
somatic diseases in autistic children

Conditions: Autistic Spectrum Disorder; Somatic Disorders

Summary: for many reasons, medical monitoring in autistic patients is very difficult. this study is designed to determine the prevalence of comorbid diseases (neurological, cardiac, digestive, dental diseases...) in patients suffering from asd to prevent them or diagnose them earlier.

mean goal : to determine the prevalence of comorbid diseases (neurological, cardiac, digestive, dental diseases...) in patients suffering from asd to prevent them or diagnose them earlier. secondary goals : * to obtain an objective assessment of the "general" monitoring in these patients (vaccinations, growth...) * to assess their habits (food, sleep, screen exposition) * to determine, in this monitoring and the habits, vigilance points which will need a specific pediatric consultation.

Eligibility criteria:
inclusion criteria: - consultation after psychiatric evaluation exclusion criteria: * age \> 18 years * impossibility to obtain the consent of parents / legal representatives.
improving the exposure therapy through projection-based augmented reality for the treatment of cockroach phobia

Conditions: Animal Phobia

Summary: the aim of this study is to test the efficacy and efficiency of varying the phobic stimuli during the augmented reality (ar) exposure therapy using multiple stimuli versus one single stimulus through projection-based ar (p-aret) for the treatment of participants diagnosed with cockroach phobia.

specific phobia (sp) refers to an extreme and persistent fear of a specific object or situation that is out of proportion to the actual danger or threat. sp is the most prevalent anxiety disorder with substantial impairment and comorbidity. animal fear is one of the most prevalent subtypes of sp. in vivo exposure is the treatment of choice for this problem, but this technique is associated to limitations in its implementation related to the access and acceptability (i.e., low acceptance on the part of patients and therapists, high dropout rates, limited access to the treatment and, difficulties in its application in the clinical context). augmented reality (ar) offers some advantages in delivering the exposure technique: 1) exposure to multiple virtual stimuli; 2) going beyond reality; 3) allowing complete control over the situation; 4) it allows privacy and confidentiality. particularly, the most significant aspect of ar is that the virtual elements add relevant and helpful information to the physical information available in the real world. the study will follow the guidelines of a multiple-baseline single case design with alternating treatments. participants (n = 4) who received a diagnosis of sp for cockroaches (dsm-5), will be randomly assigned to different baselines (ranging between 8 and 14 days) and all of them will receive the two experimental conditions: 1) ar exposure therapy with multiple stimuli and; 2) ar exposure therapy with a single stimulus. five evaluation moments will be included: pre-intervention (baseline), post- intervention, and follow-up at the first month, 6 and 12 months.

Eligibility criteria:
inclusion criteria: * being at least 18 years old * meeting dsm-5 diagnostic criteria for sp (animal subtype) to cockroaches * having a minimum of six-month duration of the phobia * sign an informed consent * presenting a score of at least 4 on the fear and avoidance scales of the diagnostic interview applied exclusion criteria: * presence of another severe mental disorder that requires immediate attention * having current alcohol or drug dependence or abuse, psychosis or severe organic illness * currently being treated in a similar treatment program * being capable of inserting their hands in a plastic container with a cockroach (during the behavioral test) * receiving other psychological treatment during the study for cockroach phobia * start receiving pharmacological treatment during the study (or in case of being already taking them, change the drug or dose)

Keywords: specific phobia cockroach phobia exposure therapy augmented reality projection-based single case study
willebrand international non-interventional global surveillance

Conditions: Von Willebrand Disease

Summary: collect information about willfact or wilfactin in their real life clinical use and identify the therapeutic practices in an international environment.

non-interventional, prospective, non comparative, international, multicentre study.

Eligibility criteria:
inclusion criteria: * patients with inherited von willebrand disease * patients treated with willfact or wilfactin * patient or parent/legal representative who has provided written signed and dated informed consent before any data collection. exclusion criteria: * patients who usually do not keep injection log up to date, when treated.

Keywords: inherited von willebrand disease von willebrand factor deficiency safety
postoperative pain assessment after using different kinematics

Conditions: Root Canal Therapy

Summary: the aim of this study is to evaluate postoperative pain after endodontic instrumentation using rotation, reciprocation and adaptive motion.

post operative pain assessment is done at the end of the session visual analog scale (vas) questionnaires were handed out to the patients and they were asked to assign a number correlating to their post-treatment pain, with 0 representing no pain and 10 representing the most severe pain imaginable.these scores were marked in intervals of 6, 12, 24, 48 and 72 h following endodontic treatment.

Eligibility criteria:
inclusion criteria: 1. medically free patients with good health. 2. patient's age between 18_50 3. mandibular first molars teeth diagnosed clinically and radiographically as acute irreversible pulpitis with no evidence of apical pathosis 4. positive patient's acceptance for participation in the study exclusion criteria: * root resorption * non restorable teeth. * pregnancy. * systematic disease as hypertension ,diabetes . * psychologically disturbance. * need for prophylactic antibiotics
awake prone positioning for severe acute chest syndrome

Conditions: Acute Chest Syndrome; Sickle Cell Anemia

Summary: acute chest syndrome (acs) is the leading cause of admission to intensive care and the leading cause of death in patients with sickle cell disease. irrespective of the cause of acs, there is an heterogeneity in pulmonary ventilation/perfusion ratios, leading to worsening of the disease. efficiency of awake prone positioning (app) in acute respiratory failure (arf) was particularly highlighted during the covid-19 pandemic. several physiological factors contribute to this benefit including an improvement in ventilatory drive and gas exchange. the investigator hypothesize that app could lead to clinical improvement in acs in terms of oxygenation and ventilatory drive, by improving the heterogeneity of ventilation

* several physiological mechanisms contribute to the benefit of app during arf. in addition to hypoxemia improvement, there is also an effect on ventilatory drive, notably in terms of polypnea, rox index and inspiratory effort. * considering that hypoxemia in acs contributes to the physiopathological process: deoxygenation of haemoglobin s - red blood cells falciformisation - vaso-occlusive event, app could be an additional therapy in severe acs. in addition, improving ventilation-perfusion ratios, mainly by recruiting dorsal zones, could be particularly useful in acs, where pulmonary damage predominates in gravito-dependent zones.

Eligibility criteria:
inclusion criteria: * age \>18 years * major sickle cell anemia (ss, sc, sβ) * admission in intensive care unit for acs * registered in the french social insurance regime. * written, informed consent exclusion criteria: * pregnant or breastfeeding women * immediate need for intubation * impaired vigilance status (glasgow scale score \< 12) * pneumothorax * haemodynamically unstable * thoracic trauma admission * severely obese with body-mass index higher than 40 kg/m² * eit contraindication: pacemaker, automatic implantable defibrillators, skin lesions facing the eit belt, unstable rachis fracture or medullary lesions

Keywords: acute chest syndrome sickle cell anemia awake prone positioning electric impedance
motivational incentives for enhanced drug abuse recovery: methadone clinics. - 1

Conditions: Substance-Related Disorders

Summary: the purpose of this study is to test the utilization of incentive values (considerably lower than those typically used in research clinics) to motivate clients to attend treatment and initiate and sustain abstinence.

the purpose of the proposed research is to implement and systematically evaluate, in community treatment settings, motivational incentive procedures that have been well researched and have proven efficacious in a variety of treatment research clinics. the study will determine if motivational incentives along with standard care therapy is more effective than standard therapy alone for the treatment of patients using cocaine or methamphetamine and entering a substance abuse treatment program.

Eligibility criteria:
inclusion criteria: 1. recent admission to an opioid substitution (methadone maintenance) ctp. completed at least 4 weeks of maintenance at time of study entry 2. evidence of cocaine or methamphetamine use minimum of one documented positive urine within 2 weeks of study entry. for those exiting a controlled environment, any stimulant use within two weeks of entering the controlled environment exclusion criteria: 1. unable to give informed consent (fails simple consent quiz) 2. answers yes to question: are you in recovery from gambling? that is, have you stopped gambling because of previous gambling problems?

Keywords: substance use disorders
a comparison between two oral hypoglycemics - metformin and glybenclamide for the treatment of gestational diabetes mellitus

Conditions: Gestational Diabetes Mellitus

Summary: rationale gestational diabetes mellitus (gdm) complicates 5-7% of pregnancies. major hazards include macrosomia, polyhydramnios, labor trauma and neonatal hypoglycemia. the ada and acog recommend glucose control in order to reduce the incidence of hyperglycemia induced complications. glucose control can be achieved using diet and life style changes. insulin is initiated in women who fail to obtain glucose control with diet alone. during the past 11 years oral hypoglycemic drugs have been tested and proven to be efficacious and safe. objectives 1. to compare the efficacy and safety of glybenclamide vs. metformin in the treatment of women diagnosed with gdm 2. to evaluate the improvement in glycemic control after the addition of a second oral hypoglycemic drug after failure of the first hypothesis gdm is one of the major conditions contributing to obstetrical complications and prenatal morbidity. improving glycemic control, by means of improving compliance and patient satisfaction, will decrease obstetrical complications, maternal and neonatal morbidity and have positive long term health implications. study design prospective, randomized, open label study population women between the ages 18-45, diagnosed with gdm will be recruited. gdm will be defined by a pathological ogtt (according to carpenter and coustan criteria) performed at or after 13 weeks of gestation. study period from recruitment until discharge of the newborn baby after delivery study protocol women will be randomized at recruitment. demographic and obstetrical data will be collected. average glucose levels during the previous two weeks, estimated fetal weight and amniotic fluid index, and lab exams reflecting glycemic control will be noted. women will provide daily glucose levels via fax or mail once a week. glycemic control will be evaluated by a daily chart, including 7 measurements: 3 preprandial, 3 postprandial and a 7th measurement at 10 pm. women will be invited to a monthly follow-up, which will include a sonographic evaluation of fetal weight and amniotic fluid, and lab exams. follow-up protocol after 38 w of gestation will be according to our ward's protocol. the study was approved by the local helsinki committee. time table duration: two years


Eligibility criteria:
inclusion criteria: 1. patients with gdm with a gestational age between 14-33 weeks 2. fasting glucose over 95 mg% or over 130 mg% an hour and a half postprandial (ppd) or a daily average over 100 mg% 3. at least a week of dietary treatment 4. sonographic dating of the pregnancy earlier than 24 weeks 5. signing a consent form exclusion criteria: 1. suspected iugr earlier than 24 week of gestation 2. major fetal malformation 3. pre-gestational diabetes mellitus
randomized evaluation of radotinib versus imatinib in phase iii study for efficacy with chinese patients (rerise china)

Conditions: Chronic Myeloid Leukemia, Chronic Phase

Summary: this is a phase iii, multi-center, open-label, parallel, 2-arm, randomized study to evaluate the efficacy and safety of radotinib 300 mg bis in die(bid) versus imatinib 400 mg quaque die(qd). this study will be conducted in chinese patients with newly diagnosed ph+ chronic myelogenous leukemia(cml)-chronic phase(cp) who are previously untreated for chronic myelogenous leukemia(cml).

patients randomized to the radotinib arms will receive 300 mg of radotinib bid at approximately 12-hour intervals. patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study. the primary efficacy endpoint is the rate of major molecular response(mmr) at 12 months (1 month = 4 weeks = 28 days), defined as bcr abl1/abl% ≤ 0.1% by international scale. the molecular response(mr) rate will be measured every 3 months by real-time quantitative(rq)-polymerase chain reaction(pcr) in a central laboratory. all patients will be treated and/or followed for 12 months (48 weeks) after randomization.

Eligibility criteria:
inclusion criteria: 1. china who are 18 years of age or older. 2. eastern cooperative oncology group (ecog) score 0, 1, or 2. 3. patients with confirmed diagnosis of cml-cp within last 6 months. 4. patients with cytogenetically confirmed ph+ cml in chronic phase 5. patients with typical bcr-abl1 transcript type such as b2a2 and b3a2. 6. patients with adequate organ function. 7. women of childbearing potential should have negative serum or urine pregnancy test within 14 days before study entry. 8. patients providing written informed consent before initiation of any study-related activities. exclusion criteria: 1. patients with philadelphia chromosome negative but bcr-abl1 positive cml. 2. patients who had been treated with interferon or other targeted anti-cancer therapy which inhibits the growth of leukemic cells 3. concurrently clinically significant primary malignancy 4. patients who previously received radiotherapy 5. patients with impaired cardiac function. 6. uncontrolled chronic medical condition
pilot study to investigate the diagnostic yield and utility of 22g and 19g endobronchial ultrasound transbronchial needle aspirate

Conditions: Non Small Cell Lung Cancer

Summary: needle biopsy samples are routinely collected to evaluate cytomorphology, immunohistochemical markers and for mutational analysis. with regular use of immunotheraputic interventions, needle biospy has become more frequent and requires bigger samples for an increasing battery of tests. there has been no clear consensus on which biopsy needle yields the best biopsy sample. it is unclear if large 19g needle offers better yield than a 22 g needle. although previous studies comparing 21, 22 and 19g needles have suggested that larger needles yield larger biopsy sizes, conflictng studies have shown that larger biopsies lead to bloodier samples with potentially smaller fragments of tissue, offering no improvement in diagnostic, yield, adequacy or sample size. this study compares biopsy samples collected using 19g and 22g needles from patients of non small cell lung cancer (nsclc) scheduled to undergo endobronchial ultrasound (ebus) and transbroncial needle aspiration (tbna).

primary objective to compare the diagnostic yield of 22g and 19g ebus transbronchial needle aspirate (tbna) secondary objectives 1. to compare the sample adequacy of 22g and 19g ebus tbna 2. to compare the sample quality of 22g and 19 g ebus tbna

Eligibility criteria:
inclusion criteria: * patients undergoing ebus tbna for evaluation of lymphadenopathy, lung nodule or mass * patients must have atypical lymph nodes. atypical lymph nodes are characterized by \>10mm in short axis or lymph nodes 5-10mm in short axis with atypical features. * age \> 18 years. * patients must have platelets count \> 50,000 * ability to understand and willingness to sign a written informed consent and hipaa consent document * wocbp must agree not to get pregnant until the day of the procedure exclusion criteria: * patients with uncorrectable coagulopathy will be excluded. * patients with hemodynamic instability will be excluded * patients with refractory hypoxemia will be excluded * patients with therapeutic anticoagulant that cannot be held for 2 days before and 1 day after the procedure. * patients who are unable to tolerate general anesthesia according to the anesthesiologist * pregnant or breast feeding.